FDA drug data now shared with patent examiners—with weak confidentiality guardrails

What it does

This bill creates a formal task force between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) to share information about drug patents and approvals. Patent examiners will gain access to FDA data on drug approvals, labeling changes, and prior art to make better patenting decisions, while the FDA will receive help organizing patent listings. The bill requires a 4-year report on how useful this coordination is and whether other agencies should join.

Why we flagged it

The bill's core function is establishing a formal information-sharing mechanism between two federal agencies to improve patent examination quality. It is neither a deregulation nor a subsidy, but rather a procedural coordination measure with both transparency and confidentiality safeguards.

What the text implies

• Patent examiners will gain access to confidential drug-sponsor information (product applications, approval communications) not subject to public disclosure. While protocols are required, the 30-day notice period may be insufficient for sponsors to object, and 'inadvertent disclosure' remedies are vague.
• The bill does not specify funding for the task force, leaving appropriations uncertain. If underfunded, the coordination may be nominal, or if well-funded, it could shift resources away from other USPTO functions.
• The FDA's 'ministerial role' in patent listing is preserved, but the task force may influence which patents get listed by providing examiners with information that affects patentability decisions upstream.
• The bill encourages expansion to 'other Federal agencies' (section 3(4)), potentially creating a broader interagency data-sharing network without explicit congressional approval for each new participant.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a genuine public benefit by improving patent examination quality through better information sharing, potentially reducing invalid patents and speeding legitimate innovation in pharmaceuticals. However, it grants patent examiners access to confidential drug-sponsor information not normally public, creating a risk that sensitive commercial data could be disclosed or misused, and the 30-day notice period may be insufficient to protect trade secrets.

Who stands to gain

• pharmaceutical companies (improved patent examination may strengthen patent protection for drugs)
• biotechnology firms (similar benefit from better prior-art assessment)

Named in the bill

U.S. Patent and Trademark Office (USPTO), Food and Drug Administration (FDA), Under Secretary of Commerce for Intellectual Property, Commissioner of Food and Drugs, House Committee on the Judiciary, Senate Committee on the Judiciary

Where it stands

• Jul 21, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 21, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $20,222,990 in lobbying spend. A filing names 37 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Joe Neguse, the sponsor, reported $1,076,229 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Bluecross Blueshield of Tennessee — $140,000 on 1 filing
• The Campaign for Sustainable Rx Pricing — $90,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.